Compositions and methods for selective phagocytosis of human cancer cells
AssigneeThe Trustees of the University of Pennsylvania
InventorsDennis E. Discher, Kyle R. Spinler, Cory Alvey
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods that provide novel therapies in cancer. The invention includes a phagocytic cell modified with a repressor of signal regulatory protein-alpha (SIRPα) and bound to a targeting antibody to enhance phagocytic activity of the phagocytic cell toward tumor tissue. Methods of enhancing phagocytic activity and treating a tumor are also included.
Claims11
A composition comprising a repressor of CD47-signal regulatory protein-alpha (CD47-SIRPa) interaction and an opsonin, wherein the composition has a therapeutic effect on a tumor tissue.
A composition comprising a signal regulatory protein-alpha (SIRPa) repressed bone marrow cell and an opsonin, wherein the composition has a therapeutic effect on a tumor tissue.
Dependencies are inferred from the claim text.